EP2377548A3 - Isolement et/ou conservation de cellules dendritiques pour l'immunothérapie du cancer de la prostate - Google Patents

Isolement et/ou conservation de cellules dendritiques pour l'immunothérapie du cancer de la prostate Download PDF

Info

Publication number
EP2377548A3
EP2377548A3 EP10183831A EP10183831A EP2377548A3 EP 2377548 A3 EP2377548 A3 EP 2377548A3 EP 10183831 A EP10183831 A EP 10183831A EP 10183831 A EP10183831 A EP 10183831A EP 2377548 A3 EP2377548 A3 EP 2377548A3
Authority
EP
European Patent Office
Prior art keywords
prostate cancer
dendritic cells
cells
human dendritic
activate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10183831A
Other languages
German (de)
English (en)
Other versions
EP2377548A2 (fr
Inventor
Gerald P. Murphy
Alton L. Boynton
Benjamin A. Tjoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwest Biotherapeutics LLC
Original Assignee
Northwest Biotherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics LLC filed Critical Northwest Biotherapeutics LLC
Publication of EP2377548A2 publication Critical patent/EP2377548A2/fr
Publication of EP2377548A3 publication Critical patent/EP2377548A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP10183831A 1995-07-31 1996-07-29 Isolement et/ou conservation de cellules dendritiques pour l'immunothérapie du cancer de la prostate Withdrawn EP2377548A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/509,254 US5788963A (en) 1995-07-31 1995-07-31 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
EP96927268A EP0841940A4 (fr) 1995-07-31 1996-07-29 Procede permettant d'isoler et/ou de conserver des cellules dendritiques pour l'immunotherapie du cancer de la prostate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP96927268.1 Division 1997-02-13

Publications (2)

Publication Number Publication Date
EP2377548A2 EP2377548A2 (fr) 2011-10-19
EP2377548A3 true EP2377548A3 (fr) 2012-10-10

Family

ID=24025874

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96927268A Withdrawn EP0841940A4 (fr) 1995-07-31 1996-07-29 Procede permettant d'isoler et/ou de conserver des cellules dendritiques pour l'immunotherapie du cancer de la prostate
EP10183831A Withdrawn EP2377548A3 (fr) 1995-07-31 1996-07-29 Isolement et/ou conservation de cellules dendritiques pour l'immunothérapie du cancer de la prostate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP96927268A Withdrawn EP0841940A4 (fr) 1995-07-31 1996-07-29 Procede permettant d'isoler et/ou de conserver des cellules dendritiques pour l'immunotherapie du cancer de la prostate

Country Status (9)

Country Link
US (2) US5788963A (fr)
EP (2) EP0841940A4 (fr)
JP (1) JP4267692B2 (fr)
AU (1) AU723607B2 (fr)
CA (1) CA2228176C (fr)
DE (1) DE841940T1 (fr)
IL (1) IL123079A0 (fr)
NZ (1) NZ315441A (fr)
WO (1) WO1997004802A1 (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US20040110283A1 (en) * 1997-02-27 2004-06-10 University Of Pittsburgh Of The Commonwealth System Of Higher Education Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
US20050170503A1 (en) * 1997-02-27 2005-08-04 University Of Pittsburgh In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
WO1999024554A2 (fr) 1997-11-12 1999-05-20 University Of Pittsburgh Isolement, caracterisation et identification de cellules de type dendritique et leurs procedes d'utilisation
WO1999043710A1 (fr) * 1998-02-26 1999-09-02 Beckman Coulter, Inc. Antigenes d'enveloppe specifiques a la prostate et procedes de preparation et d'utilisation desdits antigenes
AU3102599A (en) * 1998-03-20 1999-10-11 Genzyme Corporation Compositions and methods for the frozen storage of dendritic cells
JP2002509716A (ja) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
JP2002514420A (ja) * 1998-05-11 2002-05-21 ミクロメット・アクチェンゲゼルシャフト 樹状細胞に対する抗体およびヒト樹状細胞集団およびその使用
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US7351546B2 (en) * 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
DK1123086T3 (da) 1998-10-20 2010-06-14 Androclus Technologies S R L I Kunstige antigen-specifikke celler og tilhørende fremgangsmåder
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
EP1165144A2 (fr) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Cellules dendritiques transduites avec un gene du soi de type sauvage suscitant des reponses immunitaires antitumorales puissantes
WO2000061772A2 (fr) 1999-04-14 2000-10-19 Chiron Corporation Compositions et procedes permettant de generer une reponse immunitaire au moyen de systemes de vecteurs a base d'alphavirus
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
KR100363587B1 (ko) * 1999-11-12 2002-12-06 이시우 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
EP1813626B1 (fr) * 1999-11-15 2015-02-18 Miltenyi Biotec GmbH Fragments anticorps spécifiques aux cellules dendritiques, compositions et procédés d'utilisation de ceux-ci, antigènes ainsi reconnus et cellules ainsi obtenues
AU1811801A (en) * 1999-12-03 2001-06-12 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
WO2001074845A2 (fr) * 2000-03-31 2001-10-11 Aventis Pasteur Limited Peptides immunogenes derives d'antigene d'enveloppe specifique de la prostate (psma) et leur utilisation
IL152748A0 (en) 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
EP2363139B1 (fr) * 2000-05-12 2016-03-02 NorthWest Biotherapeutics, Inc. Procédé pour augmenter la présentation de classe I d'antigènes exogènes par cellules dendritiques humaines
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
AU2001290860A1 (en) * 2000-09-21 2002-04-02 The Regents Of The University Of California Spas-1 cancer antigen
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
WO2002034119A2 (fr) 2000-10-27 2002-05-02 Immuno-Rx, Inc. Immunotherapie vaccinale pour patients immunodeprimes
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20040191246A1 (en) 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
US20030082806A1 (en) * 2001-04-27 2003-05-01 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated T cells
DK1441591T3 (en) 2001-09-06 2017-05-22 Northwest Biotherapeutics Inc Compositions and Methods for Priming Monocytic Dendritic Cells and T-Cells for TH-1 Response
US20030143647A1 (en) * 2001-09-24 2003-07-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diagnostic methods and reagents
AU2002356844C1 (en) * 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CA2469274A1 (fr) * 2001-12-10 2003-06-19 Kyogo Itoh Antigenes tumoraux
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003241252A1 (en) * 2002-06-06 2003-12-22 Immunicum Ab New method and composition for producing a cellular allogeneic vaccine
EP1517740B1 (fr) 2002-06-19 2016-10-19 NorthWest Biotherapeutics, Inc. Dispositifs de filtration tangentielle et methodes d'enrichissement des leucocytes
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
CN1738619B (zh) * 2002-12-06 2012-04-18 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤的制药用途
JP2006519784A (ja) * 2003-01-28 2006-08-31 シャンハイ、サンウエイ、バイアテク、カムパニ、リミティド 原発癌および転移癌に対する治療（ａ２）温熱療法と腫瘍溶解の同時治療（ａ３）
PL209998B1 (pl) 2003-02-27 2011-11-30 Northwest Biotherapeutics Inc Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne
WO2005037995A2 (fr) * 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Utilisation d'un inhibiteur de cox-2 permettant d'empecher l'anergie des lymphocytes t induite par une therapie cellulaire dendritique
EP1676132B1 (fr) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center La combinaison de la chimiothérapie et de l'administration de cellules dendritiques pulsée avev gliome antigènes dans le traitement du gliome
WO2006023598A2 (fr) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
DK1778836T3 (da) * 2004-08-19 2010-11-22 Univ Cardiff Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
WO2007044033A2 (fr) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Récepteur non restreint par le cmh cloné de l'antigène spécifique de tumeur muc1 pour applications thérapeutiques et diagnostiques
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
CA2504279A1 (fr) * 2005-04-15 2006-10-15 University Of Saskatchewan Materiel et methode de modulation de la reponse immunitaire au moyen de lymphocytes t auxiliaires presentateurs d'antigene
EP1888105A2 (fr) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. Vaccins p53 permettant de traiter les cancers
CN101198620A (zh) 2005-06-17 2008-06-11 曼康公司 激发针对在癌细胞和肿瘤基质上表达的结构域和亚结构域表位的多价免疫应答的方法和组合物
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
EP1957634A4 (fr) 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc Compositions et procedes permettant d'induire l'activation de cellules dendritiques monocytiques immatures
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (fr) 2006-09-28 2017-04-18 John S. Yu Vaccins contre le cancer et methodes de vaccination
US8097242B2 (en) * 2006-10-05 2012-01-17 The Board Of Trustees Of The University Of Arkansas Target CA125 peptides for cancer immunotherapy
CA2706445C (fr) 2007-11-28 2019-07-23 Irx Therapeutics, Inc. Production de lymphocytes t resistant a l'apoptose destines a la therapie contre le cancer
EP2281004A4 (fr) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc Anticorps d'antigene membranaire specifique de la prostate et fragments de liaison a l'antigene
WO2010011994A2 (fr) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides et leurs utilisations
DK2328923T3 (en) 2008-09-02 2016-03-21 Cedars Sinai Medical Center CD133 epitopes
EP2727606A3 (fr) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Composés pour tuer des cellules cancéreuses exprimant psma et résistantes au taxane
US8697854B2 (en) 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
PT2427485T (pt) 2009-05-07 2017-03-13 Immunocellular Therapeutics Ltd Epitopos cd133
US9539320B2 (en) 2009-05-15 2017-01-10 Irx Therapeutics, Inc. Vaccine immunotherapy
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US20110251128A1 (en) * 2010-02-26 2011-10-13 The Board Of Regents Of The University Of Texas System THYMOSIN Beta4 PEPTIDES PROMOTE TISSUE REGENERATION
US9629357B2 (en) * 2013-02-01 2017-04-25 Primegen Biotech Llc Cryopreservation of cells and tissue for clinical application
WO2014127296A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Vaccins contre le cancer et méthodes de vaccination
US10320290B2 (en) * 2013-08-09 2019-06-11 Microsemi Corporation Voltage regulator with switching and low dropout modes
WO2016161441A1 (fr) 2015-04-03 2016-10-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immunothérapie combinée contre le cancer bronchique à petites cellules
US20180127717A1 (en) 2015-05-07 2018-05-10 Baylor College Of Medicine Dendritic cell immunotherapy
BR112018010006A2 (pt) 2015-11-18 2019-02-05 Orbis Health Solutions Llc sistema de expressão de gene, vetor, método para produção de uma célula-tronco pluripotente induzida e para tratamento de câncer, vacina, e, composição terapêutica.
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
WO2017181163A2 (fr) 2016-04-16 2017-10-19 Oncocyte Corporation Méthodes et compositions pour la détection et le diagnostic du cancer du sein
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (fr) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Procedes d'utilisation de cellules dendritiques pour activer des lymphocytes t

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5192553A (en) * 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
CA2158281A1 (fr) * 1993-03-15 1994-09-29 Jay A. Berzofsky Cellules dentritiques revetues de peptide, agents immunogenes
EP0765386B1 (fr) * 1994-06-14 2014-12-10 The Board Of Trustees Of The Leland Stanford Junior University Procedes pour l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsions antigeniques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (fr) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Procedes d'utilisation de cellules dendritiques pour activer des lymphocytes t

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERNHARD H ET AL: "Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood.", CANCER RESEARCH. 1 MAR 1995, vol. 55, no. 5, 1 March 1995 (1995-03-01), pages 1099 - 1104, XP002085385, ISSN: 0008-5472 *
ISRAELI R S ET AL: "EXPRESSION OF THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 54, 1 April 1994 (1994-04-01), pages 1807 - 1811, XP002910138, ISSN: 0008-5472 *
MAYORDOMO J I ET AL: "Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.", NATURE MEDICINE. DEC 1995, vol. 1, no. 12, December 1995 (1995-12-01), pages 1297 - 1302, XP000605402, ISSN: 1078-8956 *
TAYLOR M J ET AL: "THE CRYOBIOLOGY OF RAT AND HUMAN DENDRITIC CELLS: PRESERVATION AND DESTRUCTION OF MEMBRANE INTEGRITY BY FREEZING", CRYOBIOLOGY, ACADEMIC PRESS INC, US, vol. 27, no. 3, 1 June 1990 (1990-06-01), pages 269 - 278, XP001050550, ISSN: 0011-2240, DOI: 10.1016/0011-2240(90)90026-Z *
TJOA B ET AL: "In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy.", THE PROSTATE. AUG 1995, vol. 27, no. 2, August 1995 (1995-08-01), pages 63 - 69, XP000915509, ISSN: 0270-4137 *
TJOA B ET AL: "Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.", THE PROSTATE. JAN 1996, vol. 28, no. 1, January 1996 (1996-01-01), pages 65 - 69, XP000605663, ISSN: 0270-4137 *
TROYER J K ET AL: "Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen.", UROLOGIC ONCOLOGY 1995 JAN-FEB LNKD- PUBMED:21224087, vol. 1, no. 1, January 1995 (1995-01-01), pages 29 - 37, XP002682584, ISSN: 1078-1439 *
WRIGHT G L JR ET AL: "Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues", UROLOGIC ONCOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 1, 1 January 1995 (1995-01-01), pages 18 - 28, XP002205681, ISSN: 1078-1439, DOI: 10.1016/1078-1439(95)00002-Y *

Also Published As

Publication number Publication date
NZ315441A (en) 1999-06-29
CA2228176C (fr) 2015-05-26
EP0841940A4 (fr) 2005-01-05
AU6714696A (en) 1997-02-26
JP2001520633A (ja) 2001-10-30
DE841940T1 (de) 2001-08-23
US20130017600A1 (en) 2013-01-17
EP0841940A1 (fr) 1998-05-20
US5788963A (en) 1998-08-04
IL123079A0 (en) 1998-09-24
MX9800821A (es) 1998-10-31
WO1997004802A1 (fr) 1997-02-13
AU723607B2 (en) 2000-08-31
CA2228176A1 (fr) 1997-02-13
EP2377548A2 (fr) 2011-10-19
JP4267692B2 (ja) 2009-05-27

Similar Documents

Publication Publication Date Title
EP2377548A3 (fr) Isolement et/ou conservation de cellules dendritiques pour l'immunothérapie du cancer de la prostate
DK0870022T3 (da) Immunstimulerende sammensætning og fremgangsmåde
SG49113A1 (en) Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO1999011275A3 (fr) Utilisation d'oligonucleotides immunostimulants pour la prevention ou la reduction des inflammations a mediation granulocytaire et stimulees par des antigenes
WO2006050172A3 (fr) Poly-immunotherapie anticancereuse dans laquelle sont utilisees des molecules co-stimulatrices
AU2953895A (en) Multi-stage cascade boosting vaccine
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
WO2006065495A3 (fr) Methodes d'utilisation d'il-21 pour l'immunotherapie adoptive et l'identification d'antigenes tumoraux
GB9818627D0 (en) Improvements in dva vaccination
AU7392296A (en) Dendritic cell stimulatory factor
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
WO1998033527A3 (fr) Immunotherapie anticancer a base de cellules semi-allogeniques
WO1997029183A3 (fr) Procedes et compositions pour transformer des cellules dendritiques et activer des lymphocytes t
NO965395L (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
WO2001061017A3 (fr) Cytokines modifiees utilisees dans le traitement du cancer
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
CA2098113A1 (fr) Substances de nature polypeptidique pour usage therapeutique chez l'homme
WO2004026238A3 (fr) Compositions immunotherapeutiques et methodes permettant de traiter des cancers moderement a bien differencies
AU6930200A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
WO2004072262A3 (fr) Cellules presentant l'antigene cd14+ de culture
WO2000078814A3 (fr) ANTICORPS LO-CD2b ET SON UTILISATION POUR EMPECHER L'ACTIVATION ET LA PROLIFERATION DES LYMPHOCYTES T
AU6400999A (en) Antibodies to mammalian langerhans cell antigen and their uses
WO2004041297A3 (fr) Cytokines modifiees a utiliser dans la therapie contre le cancer

Legal Events

Date Code Title Description
AC Divisional application: reference to earlier application

Ref document number: 0841940

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/04 20060101ALI20120831BHEP

Ipc: A61K 39/00 20060101AFI20120831BHEP

Ipc: C07K 7/00 20060101ALI20120831BHEP

Ipc: A61K 35/55 20060101ALI20120831BHEP

Ipc: A61K 35/12 20060101ALI20120831BHEP

17P Request for examination filed

Effective date: 20130408

17Q First examination report despatched

Effective date: 20130926

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151223

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160503